Danchou
Member
- Joined
- Nov 23, 2010
- Messages
- 113
- Reaction score
- 22
- Points
- 16
PHARMACOKINETICS AND ANALGESICS EFFECTS OF PHENYLBUTAZONE IN HORSES
Nb of pages: 81
Size: 2,25 mb
SUMMARY - Horses present high predisposition to lesions in the locomotor system and consequent development of inflammatory and pain responses. Nonsteroidal anti-inflammatory phenylbutazone is one of the most used drugs in the treatment of inflammation and musculoskeletal pain in horses. The aim of this study was to evaluate the clinical effects of single intravenous administration of phenylbutazone in doses of 2.2, 4.4 or 16.6 mg/kg in horses submitted to experimental reversible lameness induced by two screws attached to horseshoe and adjusted to exert solar pressure and cause discomfort and controlled lameness. By this model, we studied plasma concentration of phenylbutazone and oxyphenbutazone and clinical response of six adult healthy horses submitted to three doses of phenylbutazone in an interval of seven days. Screws were tightened and adjusted to produce compression of the sole and induce lameness of third or fourth degree, according to the AAEP scale, staying in place for 24 hours. We have assessed lameness degree, heart rate, respiratory rate, systolic blood pressure, bowel sounds, plasma concentration of phenylbutazone and oxyphenbutazone, and hematological and biochemical parameters. All three doses of phenylbutazone demonstrated clinical efficacy without producing adverse effects. Plasma concentration of phenylbutazone and oxyphenbutazone was directly proportional to the applied dose, however the increase of dose did not increase its efficiency, since there was no difference between treatments with phenylbutazone in the reduction of the degree of lameness.
LINK
Nb of pages: 81
Size: 2,25 mb
SUMMARY - Horses present high predisposition to lesions in the locomotor system and consequent development of inflammatory and pain responses. Nonsteroidal anti-inflammatory phenylbutazone is one of the most used drugs in the treatment of inflammation and musculoskeletal pain in horses. The aim of this study was to evaluate the clinical effects of single intravenous administration of phenylbutazone in doses of 2.2, 4.4 or 16.6 mg/kg in horses submitted to experimental reversible lameness induced by two screws attached to horseshoe and adjusted to exert solar pressure and cause discomfort and controlled lameness. By this model, we studied plasma concentration of phenylbutazone and oxyphenbutazone and clinical response of six adult healthy horses submitted to three doses of phenylbutazone in an interval of seven days. Screws were tightened and adjusted to produce compression of the sole and induce lameness of third or fourth degree, according to the AAEP scale, staying in place for 24 hours. We have assessed lameness degree, heart rate, respiratory rate, systolic blood pressure, bowel sounds, plasma concentration of phenylbutazone and oxyphenbutazone, and hematological and biochemical parameters. All three doses of phenylbutazone demonstrated clinical efficacy without producing adverse effects. Plasma concentration of phenylbutazone and oxyphenbutazone was directly proportional to the applied dose, however the increase of dose did not increase its efficiency, since there was no difference between treatments with phenylbutazone in the reduction of the degree of lameness.
LINK
Last edited: